Daniel D. Von Hoff M.D., F.A.C.P.

Distinguished Professor

TGen Executive Vice President
Molecular Medicine Division

Sr. Consultant-Clinical Investigator
City of Hope

Professor of Medicine
Mayo Clinic, Clinical

Professor of Medicine
University of Arizona College of Medicine

Virginia G. Piper Distinguished Chair for Innovative Cancer Research
and Chief Scientific Officer
Honor Health Research Institute

Daniel D. Von Hoff M.D., F.A.C.P.

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Senior Consultant of Clinical Investigation at the City of Hope.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDAapproved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Publications

Zhrebker L., Cherni I., Gross L.M., Hinshelwood M., Reese M., Adrich J., Guileyardo J.M., Roberts W., Cragi D., Von Hoff D.D., Mennel R., Carpten J.D. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies BMC Cancer 2017 17:17

Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD, Han H. Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. PLoS One. 2017 Aug 25;12(8):e0183871. doi: 10.1371/journal.pone.0183871. eCollection 2017.

Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields:A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2017 Aug 1. doi: 10.1158/1078-0432.CCR-17-1117. [Epub ahead of print].

Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G,Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreaticductal adenocarcinoma. Br J Cancer. 2017 Aug 8;117(4):572-582. doi:10.1038/bjc.2017.209. Epub 2017 Jul 18.

Wang-Gilliam A., Von Hoff D.D., Siveki J., Chen A., Pippas M., Belanger A., Hubner B. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Journal of Clinical Oncology. J Clin Oncol. 2017 Feb 20;35(6):689-690. doi: 10.1200/JCO.2016.70.1607. Epub 2016 Dec 5.

Bapat A.A., Munoz R.M., Von Hoff D.D., Han H. Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells. PLoS One. 2016;11(10):e0165586

Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, S.A., Ma, W.W., Saleh, M.N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R.K., Tabernero, J., Hidalgo, M., Goldstein, D., Cutsem, E.V., Wei, X., Iglesias, J., Renschler, M.F. Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013 Oct 31; 369:1691-1703; (doi: 10.1056/NEJMoa1304369).

Xie L, Kassner M, Munoz RM, Que Q, Kiefer J, Zhao Y, Mousses S, Yin H, Von Hoff DD, and Han H. , Kinome-widesiRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol Feb 15;83(4):452-61 PMCID: PMC3265162. 2012

Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent J, Carpten J, Bubendorf L, Von Hoff DD, and Barrett MT., Advancing a Clinically Relevant Perspective of the Clonal Nature of Cancer. Proc. Natl. Acad. Sciences 108(29):12054-12059 2011

Ramanathan, RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S and Von Hoff DD., A Randomized Phase II Study of PX-12, an inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression after a Gemcitabine-Containing Combination. Can Chemo Pharmacol, Epub ahead of Print] 2010

Ramesh, A., Trevino, R., von Hoff, D., Kim, S, Clustering Context-Specific Gene Regulatory Networks. Pacific Symposium on Biocomputing, Jan 5-9, 2010, Big Island, Hawaii, US. 2010

Weiss GJ and Von Hoff DD.. , Hunting the Hedgehog Pathway Clin Pharmacol Ther Jun;87(6):743-7. 2010

Demeure MJ, Sielaff T, Koep L, Prinz R, Moser AJ, Zeh H, Hostetter G, Black J, Decker A, Rosewell R, Bussey K, Von Hoff, DD., Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimens repository Pancreas 39(7): 949-954 2010

Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G., Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9(7):2057-67 2010

Harradine KA, Kassner M, Chow D, Aziz M, Von Hoff DD, Baker J, Yin H, Pelham RJ., Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxalipatin. Mol Cancer Res Epub online 2010

Podcasts Featuring Daniel D. Von Hoff

TGen Talks Pancreatic Cancer Survivor - A four-year survivor of pancreatic ... Aug 10, 2018